Drug profile · INN
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e
AREXVY
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e (AREXVY) is a fusion glycoprotein f0 vaccine antigen.
EMA: approved Antiinfectives for systemic use (J07) J07BX05
Patents linked 0
Pipeline programs 14
News articles 0
Drug details — recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 14
- Data quality
- 0.83
Quick answer
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e (AREXVY) is a fusion glycoprotein f0 vaccine antigen.
Key facts
INN recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e
Brand AREXVY
Mechanism Fusion glycoprotein F0 vaccine antigen
Target Fusion glycoprotein F0
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BX05
Mechanism of action
Fusion glycoprotein F0 vaccine antigen
Primary target: Fusion glycoprotein F0
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e?
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e (AREXVY) is a fusion glycoprotein f0 vaccine antigen.
What is the brand name for recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e?
AREXVY is a marketed brand name for recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e. Check FDA Drugs@FDA for the current US label holder and prescribing information.